Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399) has announced its financial results for the first quarter of 2024, reporting a 5.55% year-on-year (YOY) increase in revenues to RMB 1.373 billion (USD 190.3 million). The Chinese pharmaceutical company also saw its net profits surge by 133% YOY to RMB 155 million (USD 21.5 million).
During the quarter, Hepalink’s sales expenses decreased by 45.34% YOY to RMB 92.31 million, attributed to reduced market promotion fees. Concurrently, the company’s research and development expenditure exhibited a significant increase, rising by 33.11% YOY to RMB 35.29 million. Hepalink’s cash and cash equivalents for the period stood at RMB 2.108 billion, marking a 20.25% YOY increase.- Flcube.com
